Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

If you purchased or acquired securities in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Regeneron Pharmaceuticals Inc. closed 44.20% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

The pharmaceuticals company recruits a cohort of data interns through the international IT consulting firm, challenging ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of ...